SCHEMBL4896697

SCHEMBL4896697

Cc1cc(Nc2ncc(Cl)cc2Cl)nc(-c2ccccn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 2/20 0.46
HSD17B10 Q99714 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
GPR39 O43194 3/20 0.44
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 1/20 0.44
OPRK1 P41145 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CRHR1 P34998 2/20 0.42
SLC2A1 P11166 3/20 0.41
KCNN1 Q92952 1/20 0.41
KCNN2 Q9H2S1 1/20 0.41
KCNN3 Q9UGI6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262676 0.85 KMT2A (0.47) KMT2AHTTMEN1HSD17B10CCR1
SCHEMBL1104803 0.72 CCR1 (0.64) KMT2AHTTMEN1HSD17B10CCR1
SCHEMBL3139043 0.68 SMN1; SMN2 (0.49) KMT2AHTTMEN1LMNASMN1; SMN2
SCHEMBL10953652 0.67 KDM4E (0.54) KMT2AHTTMEN1HSD17B10CCR1
SCHEMBL5256919 0.67 SLC2A1 (0.60) KMT2AHTTMEN1HSD17B10CCR1
SCHEMBL18338088 0.66 KMT2A (0.54) KMT2AHTTMEN1HSD17B10LMNA
SCHEMBL17132034 0.66 CCR1 (0.63) HTTHSD17B10CCR1CCR5CCR8
SCHEMBL28449772 0.66 KDM4E (0.52) KMT2AHTTMEN1HSD17B10CCR1
SCHEMBL5347477 0.66 CCR1 (0.55) KMT2AHTTMEN1HSD17B10CCR1
SCHEMBL517337 0.65 CCR1 (1.00) HTTHSD17B10CCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 US disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 KMT2A 563/4885HTT 1675/4885MEN1 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.